Bentham Science Logo

Track Your Manuscript:


Current Pharmacogenomics and Personalized Medicine

Formerly: Current Pharmacogenomics

Volume 17, 3 Issues, 2020
ISSN: 1875-6913 (Online)
ISSN: 1875-6921 (Print)
This journal supports open access
Order Your Article Before PrintSubscribe to this Journal

In the current pandemic scenario, publication process of all articles related to Coronavirus will be expedited, for timely publication of much needed research

Aims & Scope

Current Pharmacogenomics and Personalized Medicine (CPPM) is a transdisciplinary, peer-reviewed, biomedical journal that reports new findings and cutting-edge concepts in all areas of pharmacology. Special consideration is given to articles on pharmacogenomics and personalized medicine. CPPM is an accelerator for global personalized medicine and pharmacogenomics, as well as preclinical and clinical pharmacology. Importantly, the journal provides a multi-disciplinary, integrated platform from cell to society to address diagnostics and responsible pharmacogenomics applications in developing countries and the entire range of translational science from bench-to-bedside in various therapeutic areas such as oncology, cardiovascular, neuropharmacology, endocrine diseases, amongst others.

CPPM cooperates with the Ibero-American Network of Pharmacogenetics and the Pacific Rim Association for Clinical Pharmacogenetics and welcomes peer reviewed contributions from authors in any global region.

The journal's scope is defined by four inter-connected aims. First, we are interested in genomics/postgenomics biotechnologies and diagnostics that enable global personalized medicine science (including and beyond pharmacogenomics), as long as they explain person-to-person and population differences in disease susceptibility or response to a health intervention, and can be substantiated. Second, we approach personalized medicine as ‘personalized health interventions’ focusing primarily on drug therapy, but also other interventions such as nutrition, vaccines, surgical devices, emerging cell-based therapies that collectively contribute to healthcare. Third, we strive to integrate molecular and clinical investigation with public policy, global health diplomacy and social studies of biotechnology, that collectively shape postgenomics future(s) and innovation trajectories in life sciences. Fourth, we are interested in all aspects of translational pharmacology from preclinical to clinical applications in any therapeutic area that will advance the practice of medicine for the benefit of patients worldwide including non-communicable diseases as well as infectious diseases in the post- COVID world.

Priority will be given to expert reviews/ mini-reviews and research articles that include original ideas and findings related to the scope and mandate of the journal. Unsolicited submissions are welcomed.

Author Guidelines


Editor-in-Chief

Ramón Cacabelos
International Center of Neuroscience and Genomic Medicine
EuroEspes Biomedical Research Center
15165-Corunna
(Spain)

Biography View Full Editorial Board

Journal History

Current Pharmacogenomics was launched in 2003 and later renamed in 2008 as Current Pharmacogenomics and Personalized Medicine.

Related Journals

Related eBooks

eBooks Catalog